You are here

Seagen

Disgraced former Seagen CEO tapped to lead MorphImmune less than a year after domestic assault arrest

Disgraced former Seagen CEO tapped to lead MorphImmune less than a year after domestic assault arrest

Fierce Biotech

Purdue University

Flag link:

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

BioPharma Dive

anticompetitive practices

Flag link:

Pfizer CEO points to IRA as a factor that made Seagen an attractive target

Pfizer CEO points to IRA as a factor that made Seagen an attractive target

Endpoints

Inflation Reduction Act

Flag link:

Pfizer to buy Seagen in $43B cancer drug deal

Pfizer to buy Seagen in $43B cancer drug deal

BioPharma Dive

Flag link:

Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business

Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business

Motley Fool

Flag link:

Seagen has a New Suitor as Pfizer Talks Begin

Seagen has a New Suitor as Pfizer Talks Begin

BioSpace

Flag link:

Daiichi Sankyo gets US patent office to restart review of Seagen patent

Daiichi Sankyo gets US patent office to restart review of Seagen patent

Endpoints

Flag link:

Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris

Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris

BioSpace

Flag link:

ASCO-GU – Bicycle tries to put distance between itself and Seagen

ASCO-GU – Bicycle tries to put distance between itself and Seagen

EP Vantage

Bicycle Therapeutics

urothelial cancer

Flag link:

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Fierce Biotech

Corbus Pharmaceuticals

Flag link:

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

RAPS.org

clinical trials

clinicaltrials.gov

Flag link:

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Endpoints

Hodgkin's lymphoma

Flag link:

Seagen's highest selling drug snags a label expansion for pediatric cancer patients

Seagen's highest selling drug snags a label expansion for pediatric cancer patients

Endpoints

Hodgkin's lymphoma

Flag link:

In transition and tumult, Seagen names former Novartis oncology chief Epstein as new CEO

In transition and tumult, Seagen names former Novartis oncology chief Epstein as new CEO

Fierce Pharma

Flag link:

Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

BioPharma Dive

Lava Therapeutics

bispecific antibodies

Flag link:

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

Endpoints

Flag link:

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

Fierce Pharma

urothelial cancer

Flag link:

Merck's Deal With Seagen May Have Fallen Through. Now What?

Merck's Deal With Seagen May Have Fallen Through. Now What?

Motley Fool

Flag link:

Merck and Seagen can't agree on a price for their rumored merger

Merck and Seagen can't agree on a price for their rumored merger

Fierce Pharma

Flag link:

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

BioPharma Dive

Flag link:

Pages